- Home
- APLM vs NCRA Comparison
APLM vs NCRA Comparison
Compare APLM & NCRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- NCRA
- Stock Information
- Founded
- APLM 2016
- NCRA 2002
- Country
- APLM United States
- NCRA Taiwan
- Employees
- APLM N/A
- NCRA N/A
- Industry
- APLM Blank Checks
- NCRA Farming/Seeds/Milling
- Sector
- APLM Finance
- NCRA Consumer Staples
- Exchange
- APLM Nasdaq
- NCRA Nasdaq
- Market Cap
- APLM 15.6M
- NCRA 15.4M
- IPO Year
- APLM N/A
- NCRA N/A
- Fundamental
- Price
- APLM $0.16
- NCRA $1.17
- Analyst Decision
- APLM Strong Buy
- NCRA
- Analyst Count
- APLM 2
- NCRA 0
- Target Price
- APLM $4.25
- NCRA N/A
- AVG Volume (30 Days)
- APLM 924.9K
- NCRA 5.9K
- Earning Date
- APLM 08-14-2024
- NCRA 08-14-2024
- Dividend Yield
- APLM N/A
- NCRA N/A
- EPS Growth
- APLM N/A
- NCRA N/A
- EPS
- APLM N/A
- NCRA N/A
- Revenue
- APLM $2,101,000.00
- NCRA $26,403,874.00
- Revenue This Year
- APLM N/A
- NCRA N/A
- Revenue Next Year
- APLM N/A
- NCRA N/A
- P/E Ratio
- APLM N/A
- NCRA N/A
- Revenue Growth
- APLM 70.54
- NCRA 33.73
- 52 Week Low
- APLM $0.11
- NCRA $0.73
- 52 Week High
- APLM $3.18
- NCRA $1.60
- Technical
- Relative Strength Index (RSI)
- APLM 60.35
- NCRA 63.58
- Support Level
- APLM $0.13
- NCRA $1.16
- Resistance Level
- APLM $0.18
- NCRA $1.10
- Average True Range (ATR)
- APLM 0.01
- NCRA 0.10
- MACD
- APLM 0.00
- NCRA 0.02
- Stochastic Oscillator
- APLM 65.52
- NCRA 84.21
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About NCRA Nocera Inc.
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with expert consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.